CN112891309B - Megestrol acetate nano dry suspension and preparation method thereof - Google Patents
Megestrol acetate nano dry suspension and preparation method thereof Download PDFInfo
- Publication number
- CN112891309B CN112891309B CN201911133859.9A CN201911133859A CN112891309B CN 112891309 B CN112891309 B CN 112891309B CN 201911133859 A CN201911133859 A CN 201911133859A CN 112891309 B CN112891309 B CN 112891309B
- Authority
- CN
- China
- Prior art keywords
- megestrol acetate
- dry suspension
- parts
- auxiliary materials
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention discloses a megestrol acetate nano dry suspension which is prepared from the following components in parts by weight: 20-90 parts of megestrol acetate and 1-40 parts of auxiliary materials; wherein, in the dry suspension, the particle size of megestrol acetate is less than 400 nm. The megestrol acetate nano powder in the dry suspension has the grain diameter of less than 400nm, and the preparation has high dissolution capacity, the dissolution rate of more than 93 percent, good bioavailability and long-term storage stability. The invention also discloses a preparation method of the megestrol acetate nano dry suspension.
Description
Technical Field
The invention relates to the technical field of medicinal preparations. More particularly, relates to a megestrol acetate nano dry suspension and a preparation method thereof.
Background
Megestrol acetate is a progestational drug, is mainly used for treating advanced breast cancer and advanced endometrial cancer, and can improve appetite and cachexia of advanced tumor patients to treat renal cancer, prostatic cancer and ovarian cancer
Megestrol acetate chemical name: 6-methyl-17 alpha-hydroxypregna-4, 6-diene-3, 20-dione acetate. The molecular formula is C 24 H 32 O 4 Relative molecular mass 384.51, the structural formula is shown as follows:
megestrol acetate is classified as the Biopharmaceutical Classification System (BCS) class II due to its low solubility in water (2.0. mu.g/mL). Megestrol acetate, a poorly water soluble drug, has bioavailability that depends on the size of its particle size, in addition to its chemical nature. Due to the ultra-small volume and large specific surface area of the micrometer or nanometer megestrol acetate particles, the medicine-loading rate is higher, so that the medicine is dissolved in a human body at an accelerated speed, the targeting property and the effectiveness are improved, and the medicine absorption is finally improved. Therefore, the preparation of ultrafine particles has become an important research direction for improving the bioavailability of drugs.
In addition, the existing megestrol acetate medicine has the defects of large grain diameter of medicine particles, uneven distribution, difficulty in greatly improving the dissolution rate of the medicine, complex preparation process, high production cost and the like.
Therefore, in order to overcome the existing defects, a new megestrol acetate preparation and a preparation method thereof need to be provided.
Disclosure of Invention
Based on the above defects, the first objective of the present invention is to provide a megestrol acetate nanometer dry suspension, which contains fewer excipients, wherein the particle size of megestrol acetate nanometer powder in the dry suspension is less than 400nm (preferably between 200 and 400 nm), the preparation has high dissolution capacity, the dissolution rate is as high as more than 98%, and the preparation further has good bioavailability and long-term storage stability.
The invention also aims to provide a preparation method of the megestrol acetate nano dry suspension.
In order to achieve the first purpose, the invention adopts the following technical scheme:
the megestrol acetate nanometer dry suspension is prepared from the following components in parts by weight: 20-90 parts of megestrol acetate and 1-40 parts of auxiliary materials; wherein, in the dry suspension, the megestrol acetate particle size is less than 400 nm.
Further, the dry suspension is prepared from the following components in parts by weight: 30-85 parts of megestrol acetate and 5-35 parts of auxiliary materials.
Further, the dry suspension is prepared from the following components in parts by weight: 50-80 parts of megestrol acetate and 10-30 parts of auxiliary materials.
Further, the mass ratio of the megestrol acetate to the auxiliary materials is 1:0.1-1: 1.
Further, the mass ratio of megestrol acetate to auxiliary materials is 1:0.2-1: 0.8.
Further, the mass ratio of the megestrol acetate to the auxiliary materials is 1:0.2-1: 0.6.
Furthermore, the auxiliary material is selected from one or more of a surfactant, cellulose and derivatives thereof, and a high molecular polymer.
Further, the surfactant is an anionic surfactant.
Further, the surfactant is selected from one or more of sodium dodecyl benzene sulfonate, sodium dodecyl sulfate and tween 80.
Further, the cellulose and the derivatives thereof are selected from one or more of hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, microcrystalline cellulose and hydroxypropyl cellulose.
Further, the high molecular polymer is selected from one or more of natural water-soluble VE (vitamin E), polyvinylpyrrolidone, polyethylene glycol, vitamin E polyethylene glycol succinate, poloxamer and cross-linked polyvinylpyrrolidone.
Further, the polymer is a natural water soluble VE. Under the condition, the obtained dry suspension has smaller particle size and better bioavailability, dissolution capability and stability.
Further, the auxiliary material consists of a surfactant, cellulose and derivatives thereof according to the mass ratio of 0.5:1-2: 1; or
The auxiliary material consists of a surfactant and a high molecular polymer according to the mass ratio of 1:3-1: 5; or
The auxiliary material consists of cellulose and derivatives thereof and high molecular polymer according to the mass ratio of 1:1-1: 2. Under the condition, the obtained dry suspension has smaller particle size and better bioavailability, dissolution capability and stability.
The megestrol acetate nano dry suspension provided by the invention is a novel pharmaceutical dosage form of megestrol acetate. In the dry suspension, through the limitation on the composition and content of the raw materials of each component, the dry suspension has high dissolution capability, good bioavailability and long-term storage stability in the presence of a small amount of auxiliary materials.
In order to achieve the second purpose, the invention adopts the following technical scheme:
a preparation method of megestrol acetate nano dry suspension comprises the following steps:
and adding megestrol acetate into an aqueous solution containing auxiliary materials, and then refining and drying particles to obtain the megestrol acetate nano dry suspension.
Further, the method for refining the particles is selected from one or more of sanding, ultrasonic crushing and high-speed stirring.
Further, the sanding rotating speed is 0-3000r/min, the sanding time is 1-9h, the grinding medium used in the sanding process is one of glass beads, steel balls and zirconium silicate beads, zirconium oxide beads and pure zirconium oxide, and the size of the grinding medium is 0.1-1 mm.
Furthermore, the ultrasonic crushing power is 0-100HZ, and the ultrasonic time is 0-2 h.
Further, the high-speed stirring speed is 0-15000r/min, and the grinding time is 0-2 h.
Further, the drying is spray drying.
Further, the preparation method comprises the following steps:
dissolving the auxiliary materials in water to form a stable transparent aqueous solution;
adding megestrol acetate powder into the transparent aqueous solution to obtain megestrol acetate slurry;
thinning particles in the slurry to obtain megestrol acetate suspension;
and drying the megestrol acetate suspension to obtain the megestrol acetate nano dry suspension.
In the preparation method of the high megestrol acetate nano dry suspension provided by the invention, the megestrol acetate nano dry suspension with the effect can be prepared by combining simple grain size refinement and drying. Meanwhile, the preparation method is simple in production process, can realize large-scale production, does not need high temperature, high pressure, chemical reaction and other methods which easily damage the structure of the medicine, is mild in process conditions, and is beneficial to industrialization.
Any range recited herein is intended to include the endpoints and any number between the endpoints and any subrange subsumed therein or defined therein.
The starting materials of the present invention are commercially available, unless otherwise specified, and the equipment used in the present invention may be any equipment conventionally used in the art or may be any equipment known in the art.
The invention has the following beneficial effects:
in the dry suspension, the particle size and the dissolution performance of the nano-medicament are optimized by adjusting the composition, the concentration and the like of the auxiliary materials. The dissolution performance of the medicine is greatly improved, and the dissolution rate is more than 93 percent and can reach more than 98 percent. The megestrol acetate nano preparation has good stability and high dissolution rate, can effectively increase the accumulation of the medicine in tumor cells, improve the local medicine concentration, enhance the killing effect on the tumor cells, and is beneficial to the exertion of the medicine effect, thereby having good application prospect.
The preparation method of the dry suspension provided by the invention has a simple production process and can be used for mass production; the method which can easily destroy the components of the medicine, such as high temperature, high pressure, chemical reaction and the like, is not needed, has mild process conditions and is beneficial to industrialization.
Drawings
The following describes embodiments of the present invention in further detail with reference to the accompanying drawings.
FIG. 1 shows the scanning electron microscope image of megestrol acetate dry suspension of example 3 of the present invention.
Fig. 2 shows the particle size distribution diagram of megestrol acetate dry suspension in example 2 of the present invention.
FIG. 3 shows dissolution profiles of examples of the invention and comparative examples.
Detailed Description
In order to more clearly illustrate the present invention, the present invention is further described below with reference to preferred embodiments and the accompanying drawings. Similar components in the figures are denoted by the same reference numerals. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and is not to be taken as limiting the scope of the invention.
Example 1
The megestrol acetate dry suspension and the preparation method thereof comprise the following steps:
1g HPMC and 1.5g TPGS were weighed into 500ml deionized water to obtain a clear solution. Again, 10g of megestrol acetate drug substance was weighed out and dispersed evenly in the clear solution previously obtained. Then, the slurry obtained in the previous step is poured into a sand mill for grinding, and the grinding is carried out for 5 hours at the speed of 2500 r/min. The slurry after milling was spray dried at 120 ℃.
The megestrol acetate dry suspension prepared in the experimental example has the average particle size of 333nm and PDI of 0.207. Dissolution according to pharmacopoeia in 0.1% tween 80pbs buffer at pH 6.2 was 98.7% at 2 h. The dry suspension has the particle size of 346nm and PDI of 0.231 after being placed for 4 months, and no obvious precipitate is generated after the dry suspension is re-dissolved and stands for 3h and 7 days.
Example 2
The megestrol acetate dry suspension and the preparation method thereof comprise the following steps:
1g of sodium carboxymethylcellulose and 2g of sodium dodecylsulfate are weighed into 500ml of deionized water to obtain a clear solution. 10g of megestrol acetate drug substance are weighed again and dispersed homogeneously in the previously obtained clear solution. Then, the slurry obtained in the previous step is poured into a sand mill for grinding, and the grinding is carried out for 5 hours at the speed of 2000 r/min. The slurry after milling was spray dried at 120 ℃.
The megestrol acetate dry suspension prepared in the experimental example has the average particle size of 376nm and the PDI of 0.172. Dissolution was 95.4% according to pharmacopeia in 0.1% tween 80pbs buffer at pH 6.2 for 2 h. The particle size of the dry suspension is 391nm after the dry suspension is placed for 4 months, the PDI is 0.272, and no obvious precipitate is generated after the dry suspension is re-dissolved and stands for 3h and 7 days.
Example 2 the dry suspension particle size and its distribution are shown in figure 2.
Example 3
The megestrol acetate dry suspension and the preparation method thereof comprise the following steps:
2g of HPMC and 1g of SDS were weighed into 500ml of deionized water to obtain a clear solution. Again, 10g of megestrol acetate drug substance was weighed out and dispersed evenly in the clear solution previously obtained. And then, putting the slurry obtained in the previous step into an ultrasonic crusher for 100HZ crushing for 4 hours. The slurry after sonication was spray dried at 120 ℃.
The megestrol acetate dry suspension prepared in the experimental example has the average particle size of 383nm and the PDI of 0.236. The dissolution rate in 0.1% tween 80pbs buffer at pH 6.2 according to pharmacopoeia was 93.2% for 2 h. The dry suspension has the particle size of 397nm and the PDI of 0.241 after being placed for 4 months, and no obvious precipitate is generated after the dry suspension is dissolved and then is placed for 3 hours and 7 days. The scanning electron micrograph of the dry suspension is shown in figure 1.
Example 4
The megestrol acetate dry suspension and the preparation method thereof comprise the following steps:
1.5g PVP and 0.5g SDS were weighed into 500ml deionized water to give a clear solution. Again, 10g of megestrol acetate drug substance was weighed out and dispersed evenly in the clear solution previously obtained. Then, the slurry obtained in the previous step is poured into a sand mill for grinding, and the grinding is carried out for 7 hours at 2000 r/min. The slurry after milling was spray dried at 120 ℃.
The megestrol acetate dry suspension prepared in the experimental example has the average particle size of 357nm and the PDI of 0.232. Dissolution rate 94.8% according to pharmacopoeia in 0.1% tween 80pbs buffer at pH 6.2 for 2 h. The particle size of the dry suspension is 383nm after the dry suspension is placed for 4 months, the PDI is 0.257, and no obvious precipitate is generated after the dry suspension is dissolved and stands for 3 hours and 7 days.
Example 5
The megestrol acetate dry suspension and the preparation method thereof comprise the following steps:
2g of polyethylene glycol and 0.5g of Tween 80 were weighed into 500ml of deionized water to obtain a clear solution. 10g of megestrol acetate drug substance are weighed again and dispersed homogeneously in the previously obtained clear solution. Then, the slurry obtained in the previous step is poured into a sand mill for grinding, and the grinding is carried out for 7 hours at 2000 r/min. The slurry after milling was spray dried at 120 ℃.
The megestrol acetate dry suspension prepared by the experimental example has the average particle size of 377nm and the PDI of 0.256. The dissolution rate in 0.1% tween 80pbs buffer at pH 6.2 according to pharmacopoeia was 93.1% for 2 h. The dry suspension has the particle size of 384nm and PDI of 0.283 after being placed for 4 months, and no obvious precipitate is generated after the dry suspension is dissolved and stands for 3 hours and 7 days.
Example 6
The megestrol acetate dry suspension and the preparation method thereof comprise the following steps:
2.5g of poloxamer and 0.5g of sodium dodecylbenzenesulfonate are weighed into 500ml of deionized water to obtain a clear solution. Again, 10g of megestrol acetate drug substance was weighed out and dispersed evenly in the clear solution previously obtained. And then pouring the slurry obtained in the previous step into a high-speed stirrer for grinding, wherein the grinding is carried out for 3 hours at a speed of 10000 r/min. The slurry after milling was spray dried at 120 ℃.
The megestrol acetate dry suspension prepared in the experimental example has the average particle size of 386nm and the PDI of 0.239. Dissolution was 93.6% according to pharmacopeia in 0.1% tween 80pbs buffer at pH 6.2 for 2 h. The particle size of the dry suspension is 394nm after the dry suspension is placed for 4 months, the PDI is 0.247, and no obvious precipitate is generated after the dry suspension is dissolved and stands for 3h and 7 days.
Comparative example 1
10g of megestrol acetate raw material drug is weighed and dispersed in 500ml of deionized water. And adding the obtained slurry into a sand mill for grinding at 2500r/min for 6h, and spray-drying the ground slurry at 120 ℃.
The average particle size of the megestrol acetate dry suspension powder prepared by the experiment is 1.2 mu m, and the PDI is 1. Dissolution was 52.7% according to pharmacopeia in 0.1% tween 80pbs buffer at pH 6.2 for 2 h. The particle size of the dry suspension is 3.6 mu m after the dry suspension is placed for 4 months, the PDI is 1, the dry suspension is dissolved again and then is kept stand for 3 hours, obvious precipitation is generated, and the powder is completely precipitated after being kept stand for 7 days.
Comparative example 2
2g of hydroxypropylmethylcellulose and 1g of SDS were weighed and dissolved in 500ml of deionized water to obtain a clear solution. 10g of megestrol acetate drug substance are weighed again and dispersed homogeneously in the previously obtained clear solution. Then the slurry obtained in the previous step is spray-dried at 120 ℃.
The megestrol acetate dry suspension powder obtained in the comparative example has the average particle size of 10 mu m and the PDI of 1. Dissolution according to pharmacopoeia in 0.1% tween 80pbs buffer at pH 6.2 was 44.7% at 2 h. The particle size of the dry suspension is 10.6 micrometers after the dry suspension is placed for 4 months, the PDI is 1, the dry suspension is dissolved again and then stands for 3 hours to generate obvious precipitates, and the powder is completely precipitated after standing for 7 days.
The dissolution profiles of the dry suspensions of examples 1 and 2 and comparative examples 1 and 2 are shown in fig. 3.
Comparative example 3
1.5g HPMC and 4g TPGS were weighed into 500ml deionized water to give a clear solution. 10g of megestrol acetate drug substance are weighed again and dispersed homogeneously in the previously obtained clear solution. Then, the slurry obtained in the previous step is poured into a sand mill for grinding, and the grinding is carried out for 5 hours at the speed of 2500 r/min. The slurry after milling was spray dried at 120 ℃.
The megestrol acetate dry suspension prepared in the experimental example has the average particle size of 416nm and the PDI of 0.256. According to the pharmacopoeia, the dissolution rate is 90.4% in 0.1% Tween 80pbs buffer solution with the pH value of 6.2 for 2h, and the dry suspension is kept stand for 2 days after being redissolved, so that no obvious precipitate is generated.
Comparative example 4
3g HPMC and 6g TPGS were weighed into 500ml deionized water to obtain a clear solution. Again, 10g of megestrol acetate drug substance was weighed out and dispersed evenly in the clear solution previously obtained. Then, the slurry obtained in the previous step is poured into a sand mill for grinding, and the grinding is carried out for 5 hours at the speed of 2500 r/min. The slurry after milling was spray dried at 120 ℃.
The megestrol acetate dry suspension prepared in the experimental example has the average particle size of 518nm and the PDI of 0.315. The dissolution rate is 91.2% in 0.1% Tween 80pbs buffer solution with pH 6.2 for 2h according to pharmacopoeia, and the dry suspension is kept stand for 2 days after redissolving, without obvious precipitation.
It should be understood that the above-mentioned embodiments of the present invention are only examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention, and it will be obvious to those skilled in the art that other variations or modifications may be made on the basis of the above description, and all embodiments may not be exhaustive, and all obvious variations or modifications may be included within the scope of the present invention.
Claims (7)
1. The megestrol acetate nanometer dry suspension is characterized by being prepared from the following components in parts by weight: 20-90 parts of megestrol acetate and 1-40 parts of auxiliary materials; wherein, in the dry suspension, the megestrol acetate particle size is less than 400 nm;
the mass ratio of megestrol acetate to auxiliary materials is 1:0.1-1: 1;
the auxiliary material consists of a surfactant, cellulose and derivatives thereof according to the mass ratio of 0.5:1-2: 1; or the auxiliary material consists of a surfactant and a high molecular polymer according to the mass ratio of 1:3-1: 5; or the auxiliary material consists of cellulose and derivatives thereof and high molecular polymer according to the mass ratio of 1:1-1: 2;
the surfactant is selected from one or more of sodium dodecyl benzene sulfonate, sodium dodecyl sulfate and tween 80;
the cellulose and the derivatives thereof are selected from one or more of hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, microcrystalline cellulose and hydroxypropyl cellulose;
the high molecular polymer is selected from one or more of natural water-soluble VE, polyvinylpyrrolidone, polyethylene glycol, vitamin E polyethylene glycol succinate, poloxamer and cross-linked polyvinylpyrrolidone;
the megestrol acetate nano dry suspension is prepared by the following method:
adding megestrol acetate into an aqueous solution containing auxiliary materials, and then carrying out particle refinement and drying to obtain the megestrol acetate nano dry suspension; the method for refining the particles is selected from one or more of sand grinding, ultrasonic crushing and high-speed stirring.
2. The megestrol acetate nano dry suspension according to claim 1, which is prepared from the following components in parts by weight: 30-85 parts of megestrol acetate and 5-35 parts of auxiliary materials.
3. The megestrol acetate nano dry suspension according to claim 1, which is prepared from the following components in parts by weight: 50-80 parts of megestrol acetate and 10-30 parts of auxiliary materials.
4. The megestrol acetate nano dry suspension according to claim 1, wherein the mass ratio of the megestrol acetate to the auxiliary material is 1:0.2-1: 0.8.
5. The megestrol acetate nano dry suspension according to claim 1, wherein the mass ratio of the megestrol acetate to the auxiliary material is 1:0.2-1: 0.6.
6. The method for preparing megestrol acetate nano dry suspension according to any one of claims 1 to 5, comprising the steps of:
adding megestrol acetate into an aqueous solution containing auxiliary materials, and then carrying out particle refinement and drying to obtain the megestrol acetate nano dry suspension; the method for refining the particles is selected from one or more of sand grinding, ultrasonic crushing and high-speed stirring.
7. The method of claim 6, comprising the steps of:
dissolving the auxiliary materials in water to form a stable transparent aqueous solution;
adding megestrol acetate powder into the transparent aqueous solution to obtain megestrol acetate slurry;
thinning particles in the slurry to obtain megestrol acetate suspension;
and drying the megestrol acetate suspension to obtain the megestrol acetate nano dry suspension.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911133859.9A CN112891309B (en) | 2019-11-19 | 2019-11-19 | Megestrol acetate nano dry suspension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911133859.9A CN112891309B (en) | 2019-11-19 | 2019-11-19 | Megestrol acetate nano dry suspension and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112891309A CN112891309A (en) | 2021-06-04 |
| CN112891309B true CN112891309B (en) | 2022-07-26 |
Family
ID=76103375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911133859.9A Active CN112891309B (en) | 2019-11-19 | 2019-11-19 | Megestrol acetate nano dry suspension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112891309B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115721612A (en) * | 2021-08-26 | 2023-03-03 | 上海宣泰医药科技股份有限公司 | Enza Lu An solid preparation granule and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101242810A (en) * | 2005-06-22 | 2008-08-13 | 伊兰制药国际有限公司 | Nanoparticulate megestrol formulations |
| CN105769763A (en) * | 2016-05-25 | 2016-07-20 | 西安德天药业股份有限公司 | Megestrol acetate nanosuspension and preparation method and application thereof |
| CN105902496A (en) * | 2016-04-18 | 2016-08-31 | 沈阳药科大学 | A treating method for a nanometer suspension solidification process |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100226989A1 (en) * | 2002-04-12 | 2010-09-09 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
| US9101540B2 (en) * | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
| US20070196498A1 (en) * | 2006-02-22 | 2007-08-23 | Sherman Bernard C | Megestrol acetate suspension |
-
2019
- 2019-11-19 CN CN201911133859.9A patent/CN112891309B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101242810A (en) * | 2005-06-22 | 2008-08-13 | 伊兰制药国际有限公司 | Nanoparticulate megestrol formulations |
| CN105902496A (en) * | 2016-04-18 | 2016-08-31 | 沈阳药科大学 | A treating method for a nanometer suspension solidification process |
| CN105769763A (en) * | 2016-05-25 | 2016-07-20 | 西安德天药业股份有限公司 | Megestrol acetate nanosuspension and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112891309A (en) | 2021-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability | |
| Xu et al. | Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid–base neutralization | |
| Zu et al. | Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique | |
| Yu et al. | Sustained release of antineoplastic drugs from chitosan-reinforced alginate microparticle drug delivery systems | |
| Hou et al. | Spray-dried nanocrystals for a highly hydrophobic drug: Increased drug loading, enhanced redispersity, and improved oral bioavailability | |
| Paredes et al. | Ricobendazole nanocrystals obtained by media milling and spray drying: pharmacokinetic comparison with the micronized form of the drug | |
| Liu et al. | A wet-milling method for the preparation of cilnidipine nanosuspension with enhanced dissolution and oral bioavailability | |
| CN103211759B (en) | Puerarin nanocrystalline medical composition and preparation method thereof | |
| CN105902496A (en) | A treating method for a nanometer suspension solidification process | |
| Xie et al. | Novel redispersible nanosuspensions stabilized by co-processed nanocrystalline cellulose–sodium carboxymethyl starch for enhancing dissolution and oral bioavailability of baicalin | |
| Dhawale et al. | Formulation and evaluation porous microspheres of 5-fluorouracil for colon targeting | |
| CN102188372A (en) | Medicinal transparent nano dispersant and preparation method thereof | |
| Zhang et al. | Dry state microcrystals stabilized by an HPMC film to improve the bioavailability of andrographolide | |
| CN112891309B (en) | Megestrol acetate nano dry suspension and preparation method thereof | |
| Han et al. | A new approach to produce drug nanosuspensions CO2-assisted effervescence to produce drug nanosuspensions | |
| CN110711176A (en) | Cilnidipine nanosuspension and preparation method thereof | |
| Yang et al. | In vitro/vivo assessment of praziquantel nanocrystals: Formulation, characterization, and pharmacokinetics in beagle dogs | |
| Jeong et al. | Development of a novel celecoxib-loaded nanosuspension using a wet media milling process | |
| CN107441048A (en) | A kind of A Lishatan esters pharmaceutical composition and the preparation containing the pharmaceutical composition and preparation method thereof | |
| Hadinoto et al. | Continuous and sustainable granulation of nanopharmaceuticals by spray coagulation encapsulation in alginate | |
| CN113975246B (en) | Docetaxel for injection and preparation method thereof | |
| CN116139089A (en) | Nanometer preparation of chitosan and nanometer traditional Chinese medicine, and preparation method and application thereof | |
| Patel et al. | Degradation kinetics of high molecular weight poly (L-lactide) microspheres and release mechanism of lipid: DNA complexes | |
| CN115120571A (en) | Preparation and application of curcumin core-shell nanoparticles | |
| Papdiwal et al. | Formulation and characterization of nateglinide nanosuspension by precipitation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |